IYH - iShares US Healthcare ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
201.55
+0.26 (+0.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close201.29
Open201.85
Bid0.00 x 800
Ask0.00 x 800
Day's Range201.30 - 202.55
52 Week Range166.89 - 202.55
Volume52,881
Avg. Volume58,112
Net Assets2.2B
NAV198.31
PE Ratio (TTM)N/A
Yield1.03%
YTD Return14.44%
Beta (3y)1.00
Expense Ratio (net)0.43%
Inception Date2000-06-12
Trade prices are not sourced from all markets
  • Thermo Fisher to Offer Complete Cannabis Testing Solutions
    Market Realist10 days ago

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

  • How Abiomed’s Revenue Trended in the First Quarter
    Market Realist17 days ago

    How Abiomed’s Revenue Trended in the First Quarter

    As discussed earlier, Abiomed (ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.

  • Investopedia25 days ago

    3 ETFs for Johnson & Johnson's Healthy Breakout

    Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.

  • 4 Sector ETFs to Tap at New Highs
    Zackslast month

    4 Sector ETFs to Tap at New Highs

    While there are winners in many corners of the stock market, investors should tap the sectors that are expected to continue moving higher in the weeks ahead.

  • Estimates and Recommendations for Allergan in August
    Market Realistlast month

    Estimates and Recommendations for Allergan in August

    Analysts expect Allergan’s (AGN) adjusted EPS to be $16.29 on revenue of $15.53 billion in 2018, a 2.6% fall in revenue compared to $15.94 billion in 2017. Analysts expect the company’s adjusted net income to fall in 2018 mainly due to a fall in its gross profit margin and partially offset by a decrease in its selling, general, and administrative expenses as well as its research and development expenses. Allergan’s stock price has fallen nearly 20.2% over the last 12 months, but it’s risen ~12.8% year-to-date in 2018.

  • ETF Trends3 months ago

    Health Care ETFs Respond Positively to Jobs Report

    The latest June jobs report published by the Bureau of Labor Statistics showed an increase of 215,000 jobs--9.2 percent higher than original forecasts--with health services being one of the top beneficiaries of the increase. The jobs report revealed that the education and health services sector represented the biggest net job gainer for June--54,000 new positions created. Of that number, about 25,000 came as a result of hiring in the health care sector.

  • How Incyte’s Jakafi Performed in Q1 2018
    Market Realist4 months ago

    How Incyte’s Jakafi Performed in Q1 2018

    Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

  • Allergan’s International Business in 1Q18
    Market Realist5 months ago

    Allergan’s International Business in 1Q18

    Allergan’s (AGN) International business includes the revenues from both specialized therapeutics portfolio and general products portfolio from outside the US markets.

  • Eli Lilly’s Valuation after Its 1Q18 Earnings
    Market Realist5 months ago

    Eli Lilly’s Valuation after Its 1Q18 Earnings

    Eli Lilly (LLY) surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenues in 1Q18. Reported EPS was $1.34 on revenues of $5.7 billion, compared to the estimate for EPS of $1.14 on revenues of $5.5 billion.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist5 months ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • Johnson & Johnson’s Revenue Estimates for 1Q18
    Market Realist5 months ago

    Johnson & Johnson’s Revenue Estimates for 1Q18

    As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.

  • Key Updates on Akcea Therapeutics’ Volanesorsen
    Market Realist6 months ago

    Key Updates on Akcea Therapeutics’ Volanesorsen

    How Ionis Pharmaceuticals Is Positioned in 2018

  • ETF Trends8 months ago

    Healthcare Dip Could be a Buying Opportunity

    The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...

  • Merck’s 4Q17 Estimates: Revenue Growth Expected
    Market Realist8 months ago

    Merck’s 4Q17 Estimates: Revenue Growth Expected

    Expectations for Merck’s 4Q17 Earnings on February 2

  • Merck & Co.’s Human Vaccines Business in 3Q17
    Market Realist8 months ago

    Merck & Co.’s Human Vaccines Business in 3Q17

    Who’s Watching Merck & Co. in January 2018?

  • Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect
    Market Realist8 months ago

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect

    Johnson & Johnson’s 4Q17 Earnings on January 23: What to ExpectA look at Johnson & Johnson’s estimates

  • Developments for Ionis Pharmaceuticals Post-3Q17
    Market Realist8 months ago

    Developments for Ionis Pharmaceuticals Post-3Q17

    What's the Word on Ionis Pharmaceuticals This January?

  • How’s Incyte’s Valuation in January 2018?
    Market Realist8 months ago

    How’s Incyte’s Valuation in January 2018?

    New Insights for Incyte Corporation as of JanuaryA look at Incyte

  • Market Realist9 months ago

    How the US Economy Performed in 2017

    This year has been a year to watch the US economy. Hopes for change, tax reform, and industry-friendly policies drove the markets (SPY) higher.

  • Market Realist9 months ago

    How the Medical Expense Tax Deduction Affects the Healthcare Industry

    According to AARP, around 75% the population claiming these medical expense deductions from their income are 50 years or older.

  • iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High
    Zacks11 months ago

    iShares U.S. Healthcare ETF (IYH) Hits New 52-Week High

    This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

  • Benzingalast year

    9 Million American Children Lost Funding For Their Insurance

    In 1928, Congress passed a joint resolution establishing Child Health Day, the express purpose of which was to raise awareness “of the fundamental necessity of a year-round program to protect and develop ...